Pathogenic role of innate immunity in a model of chronic NO inhibition associated with salt overload

Imagem de Miniatura
Arquivos
art_ZAMBOM_Pathogenic_role_of_innate_immunity_in_a_model_2019.PDF (2.98 MB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER PHYSIOLOGICAL SOC
Autores
Citação
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, v.317, n.4, p.F1058-F1067, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Nitric oxide inhibition with N-omega-nitro-L-arginine methyl ester (L-NAME), along with salt overload, leads to hypertension, albuminuria, glomerulosclerosis, glomerular ischemia, and interstitial fibrosis, characterizing a chronic kidney disease (CKD) model. Previous findings of this laboratory and elsewhere have suggested that activation of at least two pathways of innate immunity, Toll-like receptor 4 (TLR4)/NF-kappa B and nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain containing 3 (NLRP3) inflammasome/IL-1 beta, occurs in several experimental models of CKD and that progression of renal injury can be slowed with inhibition of these pathways. In the present study, we investigated whether activation of innate immunity, through either the TLR4/NF-kappa B or NLRP3/IL-1 beta pathway, is involved in the pathogenesis of renal injury in chronic nitric oxide inhibition with the salt-overload model. Adult male Munich-Wistar rats that received L-NAME in drinking water with salt overload (HS + N group) were treated with allopurinol (ALLO) as an NLRP3 inhibitor (HS + N + ALLO group) or pyrrolidine dithiocarbamate (PDTC) as an NF-kappa B inhibitor (HS + N + PDTC group). After 4 wk, HS + N rats developed hypertension, albuminuria, and renal injury along with renal inflammation, oxidative stress, and activation of both the NLRP3/IL-1 beta and TLR4/NF-kappa B pathways. ALLO lowered renal uric acid and inhibited the NLRP3 pathway. These effects were associated with amelioration of hypertension, albuminuria, and interstitial inflammation/fibrosis but not glomerular injury. PDTC inhibited the renal NF-kappa B system and lowered the number of interstitial cells staining positively for NLRP3. PDTC also reduced renal xanthine oxidase activity and uric acid. Overall, PDTC promoted a more efficient anti-inflammatory and nephroprotective effect than ALLO. The NLRP3/IL-1 beta and TLR4/NF-kappa B pathways act in parallel to promote renal injury/inflammation and must be simultaneously inhibited for best nephroprotection.
Palavras-chave
chronic kidney disease, high salt, hypertension, inflammation, innate immunity, nitric oxide
URI
https://observatorio.fm.usp.br/handle/OPI/34097
Referências
  1. Arias SCA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056215
  2. Anders HJ, 2011, J AM SOC NEPHROL, V22, P1007, DOI 10.1681/ASN.2010080798
  3. Arcos MI, 2000, AM J PHYSIOL-RENAL, V279, pF1060
  4. BAYLIS C, 1992, J CLIN INVEST, V90, P278, DOI 10.1172/JCI115849
  5. Bomfim GF, 2012, CLIN SCI, V122, P535, DOI 10.1042/CS20110523
  6. Braga TT, 2017, SCI REP-UK, V7, DOI 10.1038/srep39884
  7. Brunner M, 2015, EXCLI J, V14, P439, DOI [10.17179/excli2014-151, 10.17179/excli2015-151]
  8. Correa-Costa M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014298
  9. Fang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072344
  10. Faustino VD, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180762
  11. Foresto-Neto O, 2018, LAB INVEST, V98, P773, DOI 10.1038/s41374-018-0029-4
  12. Franco M, 2013, AM J PHYSIOL-RENAL, V304, pF982, DOI 10.1152/ajprenal.00463.2012
  13. Fujihara CK, 2006, AM J PHYSIOL-RENAL, V290, pF632, DOI 10.1152/ajprenal.00259.2005
  14. FUJIHARA CK, 1994, AM J PHYSIOL, V266, pF697
  15. Fujihara CK, 2001, HYPERTENSION, V37, P170, DOI 10.1161/01.HYP.37.1.170
  16. Fujihara CK, 2007, AM J PHYSIOL-RENAL, V292, pF92, DOI 10.1152/ajprenal.00184.2006
  17. Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004
  18. Han YQ, 1999, CIRC RES, V84, P695, DOI 10.1161/01.RES.84.6.695
  19. Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5
  20. Herrington FD, 2016, J BIOMOL SCREEN, V21, P223, DOI 10.1177/1087057115617456
  21. Hu QH, 2012, BIOCHEM PHARMACOL, V84, P113, DOI 10.1016/j.bcp.2012.03.005
  22. Isaka Y, 2016, NEPHROL DIAL TRANSPL, V31, P890, DOI 10.1093/ndt/gfv024
  23. Ishola DA, 2006, KIDNEY INT, V70, P724, DOI 10.1038/sj.ki.5001629
  24. Ives A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7555
  25. Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5
  26. JEPSEN FL, 1979, VIRCHOWS ARCH A, V383, P265, DOI 10.1007/BF00430245
  27. Ji YY, 2009, CELL PHYSIOL BIOCHEM, V23, P265, DOI 10.1159/000218173
  28. Kang DH, 2002, J AM SOC NEPHROL, V13, P2888, DOI 10.1097/01.ASN.0000034910.58454.FD
  29. Kim SM, 2015, AM J PHYSIOL-RENAL, V308, pF993, DOI 10.1152/ajprenal.00637.2014
  30. Kobayashi S, 2003, BIOCHEM BIOPH RES CO, V308, P306, DOI 10.1016/S0006-291X(03)01362-7
  31. Liu HF, 2017, AM J NEPHROL, V46, P333, DOI 10.1159/000481668
  32. Liu SF, 1999, CIRCULATION, V100, P1330, DOI 10.1161/01.CIR.100.12.1330
  33. Liu Y., 2018, COMPLEXITY, V2018, P1, DOI 10.1080/15548627.2018.1531196
  34. Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2
  35. Mao KR, 2013, CELL RES, V23, P201, DOI 10.1038/cr.2013.6
  36. Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
  37. Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
  38. Matesanz N, 2007, J HYPERTENS, V25, P609, DOI 10.1097/HJH.0b013e328013e7c4
  39. Mazzali M, 2001, HYPERTENSION, V38, P1101, DOI 10.1161/hy1101.092839
  40. Mezzano SA, 2001, KIDNEY INT, V60, P1366, DOI 10.1046/j.1523-1755.2001.00941.x
  41. MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436
  42. Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
  43. Morigi M, 2002, J AM SOC NEPHROL, V13, P1179
  44. Muller DN, 2000, HYPERTENSION, V35, P193, DOI 10.1161/01.HYP.35.1.193
  45. Nair AR, 2015, EXP CELL RES, V335, P238, DOI 10.1016/j.yexcr.2015.05.011
  46. Odegaard JI, 2011, ANNU REV PATHOL-MECH, V6, P275, DOI 10.1146/annurev-pathol-011110-130138
  47. Okabe C, 2013, AM J PHYSIOL-RENAL, V305, pF155, DOI 10.1152/ajprenal.00491.2012
  48. Pekarova M, 2011, THESCIENTIFICWORLDJO, V11, P2443, DOI 10.1100/2011/321979
  49. Pellegrini C, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01405
  50. Pushpakumar S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06484-6
  51. Quiroz Y, 2001, AM J PHYSIOL-RENAL, V281, pF38
  52. Rangan GK, 2001, RENAL FAILURE, V23, P773, DOI 10.1081/JDI-100108188
  53. Rangan GK, 1999, KIDNEY INT, V56, P118, DOI 10.1046/j.1523-1755.1999.00529.x
  54. RIBEIRO MO, 1992, HYPERTENSION, V20, P298, DOI 10.1161/01.HYP.20.3.298
  55. Ricardo SD, 2008, J CLIN INVEST, V118, P3522, DOI 10.1172/JCI36150
  56. Rincon J, 2015, LIFE SCI, V124, P81, DOI 10.1016/j.lfs.2015.01.005
  57. Rodriguez-Iturbe B, 2012, CLIN EXP PHARMACOL P, V39, P96, DOI 10.1111/j.1440-1681.2011.05482.x
  58. Sainz J, 2005, AM J HYPERTENS, V18, P871, DOI 10.1016/j.amjhyper.2004.12.022
  59. SATRIANO J, 1994, J CLIN INVEST, V94, P1629, DOI 10.1172/JCI117505
  60. SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181
  61. Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
  62. Sollinger D, 2014, CARDIOVASC RES, V101, P464, DOI 10.1093/cvr/cvt265
  63. Tapia E, 2008, AM J PHYSIOL-RENAL, V295, pF1431, DOI 10.1152/ajprenal.90201.2008
  64. Tsai PY, 2011, FREE RADICAL BIO MED, V51, P744, DOI 10.1016/j.freeradbiomed.2011.05.016
  65. Vilaysane A, 2010, J AM SOC NEPHROL, V21, P1732, DOI 10.1681/ASN.2010020143
  66. Wagner CT, 1997, J CLIN INVEST, V100, P589, DOI 10.1172/JCI119569
  67. WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1
  68. Wang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038285
  69. Wang LJ, 1998, AM J PATHOL, V152, P711
  70. Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262
  71. Yang Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1413-8
  72. Zhai JX, 2012, MOL BIOL REP, V39, P6763, DOI 10.1007/s11033-012-1501-7
  73. Zhao MM, 2011, KIDNEY INT, V79, P1071, DOI 10.1038/ki.2011.18
  74. Zhu Q, 2016, AM J PHYSIOL-RENAL, V310, pF621, DOI 10.1152/ajprenal.00344.2015
  75. Zhuang YB, 2015, AM J PHYSIOL-RENAL, V308, pF857, DOI 10.1152/ajprenal.00203.2014
  76. Zoja C, 1998, KIDNEY INT, V53, P1608, DOI 10.1046/j.1523-1755.1998.00905.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - LIM/12
Artigos e Materiais de Revistas Científicas - LIM/16
Carregar mais